The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations

Liu, Yiyan

doi:10.3389/fonc.2016.00201

Cited by 92 publications

(71 citation statements)

References 43 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 F-FDG PET/CT was verified as an effective tool in diagnosis, staging, and prognosis evaluation in renal tumors. [6] However, renal malignancy is more difficult to identify than extra-renal lesions due to radioactive urine and relatively low activity of the neoplasm. In the present case, a presurgical 18 F-FDG PET/CT was performed.…”

Section: Discussionmentioning

confidence: 99%

Case report of primary renal pelvis squamous cell carcinoma coexisting with long-standing calculi in left kidney on 18F-FDG PET/CT

Deng

Zhang²,

Huang³

et al. 2017

Medicine

View full text Add to dashboard Cite

Rationale:Primary renal pelvis squamous cell carcinoma (SCC) is an extremely rare neoplasm. In many patients, the SCC was associated with renal calculi.Patient concerns:A 61-year-old male presented with intermittent pain at the left lumbar region for 3 days. The PET/CT images demonstrated increased 18F-FDG uptake in the upper pole of the left kidney and left renal hilar lymph nodes.Diagnoses:Pathologic examination revealed well-moderately differentiated renal pelvis SCC with lymphatic metastasis.Interventions:The patient underwent a left nephrectomy a few days after the initial staging PET/CT study.Outcomes:No growing lesion or metastasis was observed during a 6-month follow-up.Lessons:Our case demonstrates that 18F-FDG PET/CT is a useful diagnostic tool to evaluate primary renal pelvic SCC and detect metastatic lymph nodes in patients with long-standing calculi.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report of primary renal pelvis squamous cell carcinoma coexisting with long-standing calculi in left kidney on 18F-FDG PET/CT

Deng

Zhang²,

Huang³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Among the PET imaging agents, [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) has high sensitivity for detecting multiple malignancies, and it is routinely applied clinically for staging, restaging, and monitoring treatment . However, it shows limitations in imaging tumors in organs where glucose metabolism is high, it is not a good candidate for imaging renal carcinomas, and has shown both potential as well as pitfalls for imaging pancreatic malignancy . The short half‐life (110 min) of the 18 F isotope also precludes its shipment over long distances, and necessitates a 3‐ to 4‐fold higher amount than the required dose.…”

Section: Introductionmentioning

confidence: 99%

A Pyropheophorbide Analogue Containing a Fused Methoxy Cyclohexenone Ring System Shows Promising Cancer‐Imaging Ability

et al. 2019

View full text Add to dashboard Cite

Herein we report the synthesis, photophysical properties, positron emission tomography (PET) imaging and photodynamic therapy (PDT) efficacy of methyl 3‐(1′‐m‐iodobenzyloxy)ethyl‐3‐devinyl‐verdin 4 (with or without the 124I isotope). The PET imaging ability and ex vivo biodistribution of [124I]4 were compared with the well‐studied methyl [3‐(1241′‐m‐iodobenzyloxy)ethyl]‐3‐devinyl‐pyropheophorbide‐a methyl ester (PET‐ONCO or [124I]2) and [18F]fluorodeoxyglucose ([18F]FDG) in BALB/c mice bearing colon‐26 tumors. Whole‐body PET images of [124I]4 containing a fused methoxy cyclohexenone ring system showed excellent tumor contrast with time (72>48>24 h post‐injection). Ex vivo biodistribution results indicate that relative to the current clinical standard [18F]FDG and [124I]2 in 2 % ethanol formulation, [124I]4, at the same radioactive dose (25 μCi per mouse), showed higher tumor uptake at 24 h post‐injection and longer tumor retention. In biological environments, compound 4 showed lower fluorescence and lower singlet oxygen yield than 2, which is possibly due to higher aggregation caused by the presence of a fused cyclohexenone ring system, resulting in limited in vitro/in vivo PDT efficacy. Therefore, the chlorophyll‐a analogue [124I]4 provides easy access to a novel PET imaging agent (with no skin phototoxicity) to image cancer types—brain, renal carcinomas, pancreas—in which [18F]FDG shows limitations.

show abstract

“…Furthermore, high-grade tumors are located more accurately than low-grade tumors (Table 2) (19,21). 18F-FDG PET/CT has high sensitivity in detection of distant organ metastases and restaging RCC (Figures 1 and 2) (22). Another common indication for 18F-FDG PET/CT is evaluating response to tyrosine kinase inhibitor therapy.…”

mentioning

confidence: 99%

“…In addition, the presence of metastases may affect the mean SUV of the primary lesion. The mean SUV value of primary lesions of patients without distant organ metastasis was calculated as 2.6, compared to 5.0 for patients with distant metastases (22). Besides SUV values, metabolic parameters such as metabolic tumor volume and total lesion glycolysis calculated with PET imaging also have prognostic significance (23,24).…”

mentioning

confidence: 99%

“…Another disadvantage of conventional methods is that they require a relatively long time for treatment response to be apparent radiologically. Many publications have reported that 18F-FDG PET/CT provides a more accurate assessment than the radiologic RECIST (22,27,28,29). 18F-FDG PET/CT is particularly superior for assessing treatment response in bone metastasis because the RECIST describe soft tissue lesions (28).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Positron Emission Tomography in Renal Cell Carcinoma

Soydal¹,

Ürün²

2018

uob

View full text Add to dashboard Cite

IntroductionRenal cell carcinoma (RCC) is the most common solid kidney tumor. Contrast-enhanced computed tomography (CT) is the most frequently used imaging modality in the diagnosis, staging, and evaluation of recurrence and treatment response in patients with RCC. The overall success rate of CT for these indications is reported to be between 61% and 91% (1,2,3). However, as RCCs may appear isodense, hypodense, or hyperdense, it is difficult to distinguish benign and malignant renal masses by morphological methods (4). Magnetic resonance imaging (MRI) is recommended in cases where CT is contraindicated, such as patients who have contrast allergy or are pregnant. However, MRI is no more accurate than CT. This increases the importance of positron emission tomography (PET), which enables metabolic evaluation in addition to visualizing anatomic changes. In this review, we discuss currently available literature data regarding the use of PET applications with different radiopharmaceuticals in patients with RCC. Applications of Positron Emission Tomography in Renal Cell Carcinoma 18-Fluorine-Fluorodeoxyglucose Positron Emission TomographyPET is a metabolic imaging method that utilizes various positron-emitting radiopharmaceutical and can provide data on many different metabolic pathways. The most widely used radiopharmaceutical is a fluorodeoxyglucose molecule (FDG) labeled with 18-fluorine (18F). The modality is based on the principle of visualizing elevated glycolysis and glucose uptake in neoplastic tissues. Despite high success rates in many solid organ malignancies, the use of 18F-FDG for urinary system malignancies is limited due to excretion via the urinary tract. The first cases related to the use of 18F-FDG PET in RCC were described by Wahl et al. (5) in the early 1990s. The use of 18F-FDG PET in the detection of primary RCC is especially controversial (6,7,8,9,10). High and variable levels of background renal activity make it difficult to detect the primary focus. Forced diuresis with hydration may increase the sensitivity Renal cell carcinoma is the most common solid kidney tumor. Conventional methods such as computed tomography and magnetic resonance imaging are usually chosen for diagnosis, staging, and evaluating recurrence and treatment response. However, the sensitivity of these methods is limited in each indication. For this reason, metabolic evaluation with positron emission tomography has an important value in most solid tumors. However, the role of 18-fluorine-fluorodeoxyglucose (18F-FDG), which is the most commonly used positron emission tomography (PET) radiopharmaceutical, is limited in the evaluation of primary kidney lesions due to urinary excretion. Therefore, new radiopharmaceuticals with no or limited urinary excretion have been developed. In this paper, the application of PET imaging with the widely used 18F-FDG and the newly developed fluorothymidine and gallium-68/18F prostate-specific membrane antigen in renal cell carcinoma are reviewed.

show abstract

The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations

Cited by 92 publications

References 43 publications

Case report of primary renal pelvis squamous cell carcinoma coexisting with long-standing calculi in left kidney on 18F-FDG PET/CT

Case report of primary renal pelvis squamous cell carcinoma coexisting with long-standing calculi in left kidney on 18F-FDG PET/CT

A Pyropheophorbide Analogue Containing a Fused Methoxy Cyclohexenone Ring System Shows Promising Cancer‐Imaging Ability

Positron Emission Tomography in Renal Cell Carcinoma

Contact Info

Product

Resources

About